



mm 11/21/02 5673-60738 153887.doc

RECEIVED

DEC 10 2002

TECH CENTER 1600/2900

PATENT
Attorney Reference Number 5673-60738

Gf 1633

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Boursnell et al.

Art Unit: 1633

Application No. 09/917,176

CERTIFICATE OF MAILING

Filed: July 27, 2001

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on November 21, 2002, as First Class Mail in an envelope addressed to:
COMMISSIONER FOR PATENTS, WASHINGTON D.C. 20231.

For: VIRAL PREPARATIONS, VECTORS,
IMMUNOGENS, AND VACCINES

Examiner: To be assigned

Date: November 21, 2002

Susan Alpert Siegel, Ph.D.
Agent for Applicant

RECEIVED

NOV 29 2002

TRANSMITTAL LETTER

COMMISSIONER FOR PATENTS
WASHINGTON, DC 20231

TECH CENTER 1600/2900

Enclosed for filing in the application referenced above are the following:

- ☒ Information Disclosure Statement
- ☒ Form 1449
- ☒ The Director is hereby authorized to charge any additional fees that may be required, or credit over-payment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed.
- ☒ Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

Susan Alpert Siegel, Ph.D.
Registration No. 43,121

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

cc: Docketing



5673-60738 154005.doc

RECEIVED
DEC 10 2002
TECH CENTER 1600/2900

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Bournnell et al.

Application No. 09/917,176

Filed: July 27, 2001

For: VIRAL PREPARATIONS, VECTORS,
IMMUNOGENS, AND VACCINES


Examiner: To be assigned

Date: November 21, 2002

Art Unit: 1633

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on November 21, 2002 as First Class Mail in an envelope addressed to:
COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231.


Susan Alpert Siegel, Ph.D.
Agent for Applicant

INFORMATION DISCLOSURE STATEMENT
FOR CONTINUING APPLICATIONS

RECEIVED

NOV 29 2002

TECH CENTER 1600/2900

COMMISSIONER FOR PATENTS
WASHINGTON, DC 20231

Sir:

Listed on the accompanying form PTO-1449 are several English-language documents.

Applicants respectfully request that such documents be listed as references cited on the issued patent.

The present application relies upon U.S. Patent Application No. 09/033,549, which was filed March 2, 1998, for an earlier filing date under 35 U.S.C. § 120. Furthermore, documents listed on the accompanying PTO-1449 Form were disclosed to or cited by the Patent Office in the earlier U.S. application. As a result, copies of the documents cited on the accompanying form PTO-1449 Form need not be sent to the Patent Office pursuant to 37 C.F.R. § 1.98(d). However, applicants will furnish the Patent Office with such copies upon request.

Please charge any additional fees which may be required in connection with filing this


Information Disclosure Statement, or credit any overpayment, to Deposit Account No. 02-4550.

A **duplicate** copy of this sheet is enclosed.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By



Susan Alpert Siegel, Ph.D.
Registration No. 43,121

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

BY APPLICANT

App: 09/917,176

Filed: July 27, 2001

Art Unit: 1633

U.S. PATENT DOCUMENTS

[illegible]

DATE _____

RECEIVED
DEC 10 2002
CH CENTER 1600/2900

RECEIVED		
NOV 29 2002		
TECH CENTER 1600/2900		

**INFORMATION DISCLOSURE
STATEMENT**
BY APPLICANT

Docket: 5673-60738

App: 09/917,176

Applicant: Bournnell et al.

Filed: July 27, 2001

Art Unit: 1633

FOREIGN PATENT DOCUMENTS

	Number	Date	Country	Class	Sub		
	WO 92/05263	04/02/1992	WIPO				
	WO 93/19191	09/30/1993	WIPO				
	WO 94/21807	09/29/1994	WIPO				
	WO 94/29469	12/22/1994	WIPO				
	WO 95/03399	02/02/1995	WIPO				
	WO 96/26267	08/29/1996	WIPO				
	WO 97/20935	06/12/1997	WIPO				

OTHER DOCUMENTS

		Bellone et al., "In vitro priming of cytotoxic T lymphocytes against poorly immunogenic epitopes by engineered antigen-presenting cells," <i>Eur. J. Immunol.</i> , Vol. 24, pp. 2691-2698 (1994)
		Colombo et al., "Tumor cells engineered to produce cytokines or cofactors as cellular vaccines: do animal studies really support clinical trials?" <i>Cancer Immunol Immunother.</i> , Vol. 41, pp. 265-270 (1995)
		Danos et al., "Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 85, pp. 6460-6464 (1988)
		DeLuca et al., "Isolation and Characterization of Deletion of Mutants of Herpes Complex Virus Type 1 in the Gene Encoding Immediate-Early Regulatory Protein ICP4," <i>Journal of Virology</i> , Vol. 56, No. 3, pp. 558-570 (1985)
		Forrester et al., "Construction and Properties of a Mutant of Herpes Simplex Virus Type 1 with Glycoprotein H Coding Sequences Deleted," <i>Journal of Virology</i> , Vol. 66, No. 1, pp. 341-348 (1992)

EXAMINER:

DATE

*Examiner: Initial if considered, whether or not in conformance with MPEP 609; draw line through cite if not in conformance and not considered. Send copy.

INFORMATION DISCLOSURE STATEMENT

BY APPLICANT

Docket: 5673-60738

App: 09/917,176

Applicant: Bourns et al.

Filed: July 27, 2001

Art Unit: 1633

TECH CENTER 1600/LAW

NOV 29 2002

OTHER DOCUMENTS

Fuller et al., "Neutralizing Antibodies Specific for Glycoprotein H of Herpes Simplex Virus Permit Viral Attachment to Cells but Prevent Penetration," *Journal of Virology*, Vol. 63, No. 8, pp. 3435-3443 (1989)

Gansbacher et al., "Retroviral Vector-mediated γ -Interferon Gene Transfer into Tumor Cells Generates Potent and Long Lasting Antitumor Immunity," *Cancer Research*, Vol. 50, pp. 7820-7825 (1990)

Gao et al., "Genetic Evidence for Multiple Nuclear Functions of the Herpes Simplex Virus ICP8 DNA-Binding Protein," *Journal of Virology*, Vol. 63, No. 12, pp. 5258-5267 (1989)

Glick et al., "Molecular Biotechnology: Principles and Applications of Recombinant DNA," *American Society of Microbiology*, Chapter 17, pp. 406-415 (1994)

Günzburg et al., "Virus vector design in gene therapy," *Molecular Medicine Today*, pp. 410-417 (1995)

Hutchinson et al., "A Novel Herpes Simplex Virus Glycoprotein, gL, Forms a Complex with Glycoprotein H (gH) and Affects Normal Folding and Surface Expression of gH," *Journal of Virology*, Vol. 66, No. 4, pp. 2240-2250 (1992)

Jolly, "Viral vector systems for gene therapy," *Cancer Gene Therapy*, Vol. 1, No. 1, pp. 51-64 (1994)

Khattar et al., "Identification and Characterization of a Bovine Herpesvirus-1 (BHV-1) Glycoprotein gL Which Is Required for Proper Antigenicity, Processing, and Transport of GHB-1 Glycoprotein gH," *Virology*, Vol. 219, pp. 66-76 (1996)

Mastrangelo et al., "Gene Therapy for Human Cancer: An Essay for Clinicians," *Seminars in Oncology*, Vol. 23, No. 1, pp. 4-21 (1996)

EXAMINER:

DATE

*Examiner: Initial if considered, whether or not in conformance with MPEP 609; draw line through cite if not in conformance and not considered. Send copy.

**INFORMATION DISCLOSURE
STATEMENT**

BY APPLICANT

Docket: 5673-60738

App: 09/917,176

Applicant: Bournnell et al.

Filed: July 27, 2001

Art Unit: 1633

OTHER DOCUMENTS

McCarthy et al., "Herpes Simplex Virus Type 1 ICP27 Deletion Mutants Exhibit Altered Patterns of Transcriptions and Are DNA Deficient," *Journal of Virology*, Vol. 63, No. 1, pp. 18-27 (1989)

McGeoch, "The Genomes of the Human Herpesvirus: Contents, Relationships, and Evolution," *Annu. Rev. Microbiol.*, Vol. 43, pp. 235-265 (1989)

Pardoll, "Cancer Vaccines," *TiPS*, Vol. 14, pp. 202-207 (1993)

Robertson, "Technology evaluation: DISC," *Current Opinion in Molecular Therapeutics*, Vol. 1, No. 1, pp. 112-114 (1999)

Smith et al., "Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen," *Nature*, Vol. 302, pp. 490-495 (1983)

Verma et al., "Gene therapy – promises, problems and prospects," *Nature*, Vol. 389, pp. 239-242 (1997)

Zitvogel et al., "Construction and Characterization of Retroviral Vectors Expressing Biologically Active Human Interleukin-12," *Human Gene Therapy*, Vol. 5, pp. 1493-1506 (1994)

RECEIVED

NOV 29 2002

TECH CENTER 1600/2900

EXAMINER:

DATE

*Examiner: Initial if considered, whether or not in conformance with MPEP 609; draw line through cite if not in conformance and not considered. Send copy.